Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Receivables - Accured (2022 - 2024)

Kezar Life Sciences' Receivables - Accured history spans 3 years, with the latest figure at $589000.0 for Q3 2024.

  • For Q3 2024, Receivables - Accured changed N/A year-over-year to $589000.0; the TTM value through Sep 2024 reached $589000.0, changed N/A, while the annual FY2023 figure was $695000.0, 10.21% down from the prior year.
  • Receivables - Accured for Q3 2024 was $589000.0 at Kezar Life Sciences, up from $374000.0 in the prior quarter.
  • Across five years, Receivables - Accured topped out at $774000.0 in Q4 2022 and bottomed at $374000.0 in Q2 2024.
  • The 3-year median for Receivables - Accured is $648000.0 (2024), against an average of $616000.0.
  • The largest YoY upside for Receivables - Accured was 10.21% in 2023 against a maximum downside of 10.21% in 2023.
  • A 3-year view of Receivables - Accured shows it stood at $774000.0 in 2022, then decreased by 10.21% to $695000.0 in 2023, then fell by 15.25% to $589000.0 in 2024.
  • Per Business Quant, the three most recent readings for KZR's Receivables - Accured are $589000.0 (Q3 2024), $374000.0 (Q2 2024), and $648000.0 (Q1 2024).